Back to top
more

GlycoMimetics (GLYC)

(Delayed Data from NSDQ)

$1.64 USD

1.64
1,014,018

-0.07 (-4.09%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.76 +0.12 (7.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GLYC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

GlycoMimetics, Inc. [GLYC]

Reports for Purchase

Showing records 121 - 140 ( 157 total )

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 121

11/21/2019

Company Report

Pages: 7

As Upro''s Timeline Shifts, We Lower Our PT to $9, but Remain Buy Rated

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 122

11/14/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 123

11/13/2019

Company Report

Pages: 9

2020 Is Unlikely to Mimic 2019. Resuming Coverage with Buy Rating $12 PT

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 124

11/08/2019

Company Report

Pages: 8

3Q19; Seven Abstracts at ASH; Focus on Uproleselan in AML

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 125

08/05/2019

Company Report

Pages: 7

Rivipansel RESET Phase 3 Trial in SCD Fails; Lowering PT to $18 From $23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 126

08/02/2019

Company Report

Pages: 8

2Q19 Results; Rivipansel Topline Data Expected This Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 127

05/28/2019

Company Report

Pages: 4

We are transferring coverage, placing shares Under Review, and removing our price target and estimates

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 128

05/06/2019

Daily Note

Pages: 3

Phase 3 Rivipansel Trial Fully Enrolled

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 129

05/03/2019

Company Report

Pages: 6

Spotlight on New Clinical Program

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 130

05/02/2019

Company Report

Pages: 8

1Q19 Results; All Eyes on Rivipansel but Attention Should Be Paid to Uproleselan as Well

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 131

04/23/2019

Company Report

Pages: 7

First Patient Enrolled in Phase 3 NCI-sponsored Uproleselan AML Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 132

04/12/2019

Daily Note

Pages: 3

GMI-1359 Trial in Breast Cancer Expected to Start 2H19

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 133

03/07/2019

Company Report

Pages: 8

Reports 4Q18 Results; Program Updates, PT to $23 From $24

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 134

03/04/2019

Daily Note

Pages: 2

California DreaminÂ’ I: Biotech Stories To Keep An Eye On

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 135

01/02/2019

Industry Report

Pages: 2

Healthcare - It''s All About the Benjamins

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 136

12/18/2018

Company Report

Pages: 33

Carbohydrate-Based Approach in SCD, Hematologic Cancers; Initiating Coverage With a Buy Rating and $24 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 75.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 137

11/25/2018

Industry Report

Pages: 4

Healthcare -New Leukemia Approvals - Their Implications

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 138

11/05/2018

Company Report

Pages: 7

Focus on Sickle Cell Pivotal Data in 2Q19; Maintain Buy

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 139

11/05/2018

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 140

06/26/2018

Industry Report

Pages: 3

Healthcare - ORD-ARN-JFK: Crossing Our Onco Radar

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party